Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997320 | 0.84 | L3MBTL1 (0.41) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL9965967 | 0.81 | MAPT (0.52) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL9963371 | 0.78 | MAPT (0.50) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL7768463 | 0.77 | MAPT (0.46) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL14048238 | 0.74 | POLB (0.47) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL23222367 | 0.72 | MAPT (0.42) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL8367476 | 0.72 | KDM4E (0.47) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL19002424 | 0.71 | POLB (0.45) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL14759259 | 0.71 | POLB (0.47) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL25319495 | 0.71 | POLB (0.47) | L3MBTL1MAPTKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | L3MBTL1 4299/4885MAPT 2604/4885KDM4E 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.